BioVersys (BIOV) Stock Overview
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BIOV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioVersys AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 28.50 |
| 52 Week High | CHF 37.00 |
| 52 Week Low | CHF 24.40 |
| Beta | 0 |
| 1 Month Change | -9.81% |
| 3 Month Change | -20.39% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOV | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -6.6% | 7.7% | 3.1% |
| 1Y | n/a | 12.8% | 3.4% |
Return vs Industry: Insufficient data to determine how BIOV performed against the Swiss Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how BIOV performed against the Swiss Market.
Price Volatility
| BIOV volatility | |
|---|---|
| BIOV Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: BIOV's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: BIOV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 29 | Marc Gitzinger | www.bioversys.com |
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections.
BioVersys AG Fundamentals Summary
| BIOV fundamental statistics | |
|---|---|
| Market cap | CHF 166.61m |
| Earnings (TTM) | -CHF 19.36m |
| Revenue (TTM) | CHF 1.31m |
Is BIOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV income statement (TTM) | |
|---|---|
| Revenue | CHF 1.31m |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 1.31m |
| Other Expenses | CHF 20.67m |
| Earnings | -CHF 19.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,478.84% |
| Debt/Equity Ratio | 25.8% |
How did BIOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/07 10:43 |
| End of Day Share Price | 2025/10/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVersys AG is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jelena Milovic | Citigroup Inc |
| Clemence Thiers | Stifel, Equities Research |
| Xian Deng | UBS Investment Bank |